NEW MARKERS FOR EARLY DIAGNOSIS OF OVARIAN CANCER, MONITORING DURING THERAPY, AND NEW THERAPY OPTIONS DURING AND AFTER CHEMATHERAPY

摘要

The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. They have shown that serum assays for the proteases and protease inhibitor can be used for early detection of ovarian cancer, and for monitoring cancer treatment.